Investor relationsStormont would not be hiring an investor relations specialist if there was not going to be an increase in actionable news over the forseeable future. Up until now communication with shareholders has been pathetic. I for one look forward to future developments reaching a wider audience. For a hint of whats coming just look back to the news release of February 1, 2010. The latest NCI results are just the tip of the iceberg of potential news,,,
"the company has under way a range of testing activities designed to further characterize the action of GAP-107B8, including pharmacokinetics; drug distribution; the effect on cell signalling pathways in different cancers and in comparison with existing cancer drugs; cardiotoxicity; toxicity in rats using intravenous infusion pumps; and development of large volume, stable and consistent manufacturing processes. The data and processes developed will provide insight and direction into the continuing test program and to meet regulatory requirements for first clinical trial applications, anticipated in 2011. These program activities are directed by the company's clinical advisory group, and are being delivered under contract with independent firms in California, Arizona, Massachusetts, New York and in Ottawa.
On top of all this there is the Melanoma work at Sloan Kettering in NYC, the mouse testing in Ottawa (ovarian) and we havent heard anything about a collaboration going on in Switzerland (MD Bioscience) either.